Douglas G. Evans serves as Independent Chairman of the Board of the Company. has been a member of our Board since April 2020. Mr. Evans has served as the President and Chief Executive Officer of Lungpacer Medical Inc., a medical device company, since January 2014. Prior to joining Lungpacer, Mr. Evans served as the Chief Operating Officer and a member of the board of directors of Kensey Nash Corporation, a medical device company, from March 1995 to June 2013. Mr. Evans currently serves on the board of directors of Intact Vascular, a medical device company. Mr. Evans holds a Master of Science degree in Electrical Engineering and Photonics from the University of Pennsylvania, a M.B.A. from Pennsylvania State University Great Valley School of Graduate Professional Studies and a Bachelor’s of Science in Engineering Sciences from the Pennsylvania State University Skills & Qualifications: Mr. Evans’ extensive executive leadership experience, deep knowledge of the medical device field and his experience with the commercialization of medical products provide him with the qualifications and skills to serve on our Board.
Douglas Evans is 56, he's been the Independent Chairman of the Board of TELA Bio since 2020. There are 5 older and 10 younger executives at TELA Bio. The oldest executive at TELA Bio, Inc. is Maarten Persenaire, 63, who is the Co-Founder, Chief Medical Officer.
Douglas's mailing address filed with the SEC is C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355.
Over the last 5 years, insiders at TELA Bio have traded over $4,222,376 worth of TELA Bio stock and bought 4,343,227 units worth $46,898,981 . The most active insiders traders include Management Inc. Opaleye, Investments, Lpwong Roderic..., and Advisors Llc Orbi Med Capit.... On average, TELA Bio executives and independent directors trade stock every 18 days with the average trade being worth of $139,070. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 28 June 2024, trading 428,300 units of TELA stock currently worth $2,021,576.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Bio executives and other stock owners filed with the SEC include: